Compare Stanley Black & Decker, Inc. (SWK) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stanley Black & Decker, Inc. vs Viatris Inc — how do they compare? Stanley Black & Decker, Inc. trades at $102.7 (market cap $15.71B), while Viatris Inc trades at $16.25 (market cap $18.69B). The key difference: Viatris Inc is the larger of the two by market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.23%). Which is the better fit depends on your goals.
| SWK | VTRS | |
|---|---|---|
Market Cap | $15.71B | $18.69B |
52-Week High | $104.00 | $17.86 |
52-Week Low | $62.12 | $9.49 |
Enterprise Value | $19.87B | $30.80B |
Dividend Yield | 3.23% | 2.95% |
Sector | — | Health |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SWK trades at $102.9, up 0.25% today, with a bullish technical signal from moving averages but overbought RSI levels near 80. The company reported strong Q2 2026 earnings, beating EPS estimates with $1.57 versus $1.21 expected, and raised full-year guidance. Revenue for 2025 was $15.13B, with net income margin improving to 2.65%. Recent news highlights a $1 billion U.S. investment plan and institutional buying, supporting positive momentum.
The outlook is cautiously optimistic, with earnings growth and margin expansion driving potential upside, though the stock trades above the consensus price target of $93.67. Risks include debt levels and economic sensitivity, but institutional accumulation and dividend stability offer support. The current price near resistance at $105 may limit near-term gains despite fundamental improvements.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
